Maris J M, White P S, Beltinger C P, Sulman E P, Castleberry R P, Shuster J J, Look A T, Brodeur G M
Division of Oncology, Children's Hospital of Philadelphia, University of Pennsylvania, Philadepphia School of Medicine 19104, USA.
Cancer Res. 1995 Oct 15;55(20):4664-9.
We analyzed 156 primary neuroblastoma tumor samples for loss of heterozygosity at the distal short arm of chromosome 1 (1p LOH). We also compared 1p LOH with known clinical and genetic prognostic variables as well as patient outcome. 1p LOH was detected in 30 of 156 tumors (19%) and was strongly associated with adverse clinical and biological features. 1p LOH was also strongly predictive of a poor outcome in univariate analyses (estimated 4-year survival, 32 +/- 10% SE versus 76 +/- 5% SE; P < 0.001). However, the prognostic value of 1p LOH was equivocal when stratified for amplification of the MYCN oncogene (P = 0.16). We conclude that 1p LOH is an important component of a pattern of genetic abnormalities in neuroblastoma associated with an aggressive clinical course.
我们分析了156份原发性神经母细胞瘤肿瘤样本,以检测1号染色体短臂远端的杂合性缺失(1p LOH)。我们还将1p LOH与已知的临床和遗传预后变量以及患者预后进行了比较。在156个肿瘤中的30个(19%)检测到1p LOH,其与不良临床和生物学特征密切相关。在单变量分析中,1p LOH也强烈预示预后不良(估计4年生存率,32±10%SE对76±5%SE;P<0.001)。然而,当根据MYCN癌基因扩增进行分层时,1p LOH的预后价值并不明确(P = 0.16)。我们得出结论,1p LOH是与侵袭性临床病程相关的神经母细胞瘤遗传异常模式的一个重要组成部分。